5-(1-hydroxy-2-(2,4,5-trifluorophenyl)ethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione.
1 Results Found
Sitagliptin is an orally available, competitive, beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) with hypoglycemic activity. Sitagliptin may cause an increased risk in the development of pancreatitis. (Ref. NCI Thesaurus (NCIt) )
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other oral hypoglycemic agents. (Ref. LiverTox)
Sitagliptin is a triazolopyrazine that exhibits hypoglycemic activity. It has a role as a serine proteinase inhibitor, a hypoglycemic agent, an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor, an environmental contaminant and a xenobiotic. It is a triazolopyrazine and a trifluorobenzene. (Ref.Pub chem)
Sitagliptin API Reference standards and its EP Impurities, USP Impurities, non pharmacopeial Impurities, listed below & also offered custom synthesis for unknown Impurities. If require for any degradation Impurities contact info@drjcrbio.com, sales@drjcrbio.com
-
Free
Product Name : 5-(1-hydroxy-2-(2,4,5-trifluorophenyl)ethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione.|764667-64-3
Code: JCSIT-27 CAS: 764667-64-3 Chemical Formula: C₁₄H₁₁F₃O₅ Molecular Weight: 316.23 Category: Reference Standards/API Drug Metabolites/EP Impurities/USP Impurities Literature: Application: 5-(1-hydroxy-2-(2,4,5-trifluorophenyl)ethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione.|764667-64-3is useful as reference Impurity standard. 
